Online citations, reference lists, and bibliographies.

The Molecular Landscape Of Recurrent And Metastatic Head And Neck Cancers: Insights From A Precision Oncology Sequencing Platform

L. Morris, R. Chandramohan, Lyndsay West, A. Zehir, Debyani Chakravarty, D. Pfister, R. Wong, N. Lee, E. Sherman, S. Baxi, I. Ganly, B. Singh, J. Shah, A. Shaha, J. Boyle, S. Patel, B. Roman, C. Barker, S. Mcbride, T. Chan, S. Dogan, D. Hyman, M. Berger, D. Solit, N. Riaz, A. Ho
Published 2017 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Importance Recurrent and/or metastatic head and neck cancer is usually incurable. Implementation of precision oncology for these patients has been limited by incomplete understanding of the molecular alterations underlying advanced disease. At the same time, the molecular profiles of many rare head and neck cancer types are unknown. These significant gaps in knowledge need to be addressed to rationally devise new therapies. Objective To illuminate the distinct biology of recurrent and metastatic head and neck cancers and review implementation of precision oncology for patients with advanced disease. Design, Setting, and Participants After exclusions, 151 patients with advanced, treatment-resistant head and neck tumors, including squamous cell carcinoma (HNSCC), adenoid cystic carcinoma (ACC), and other salivary and cutaneous cancers, whose tumors were sequenced between January 2014 and July 2015 at Memorial Sloan Kettering were recruited. Next-generation sequencing of tumors as part of clinical care included high-depth (median 600×) exonic coverage of 410 cancer genes and whole-genome copy number analysis. Interventions Next-generation sequencing of tumors and matched normal DNA. Main Outcomes and Measures Feasibility, the frequency of actionable molecular alterations, the effect on decision making, and identification of alterations associated with recurrent and metastatic disease. Results Overall, 151 patients (95 men and 56 women; mean [range] age, 61.8 [17-100] years) were included in the study. Next-generation sequencing ultimately guided therapy in 21 of 151 patients (14%) (13 of 53 [25%] of patients with HNSCC) by refining diagnoses and matching patients to specific therapies, in some cases with dramatic responses on basket studies. Molecular alterations were potentially actionable in 28 of 135 patients (21%). The genetic profiles of recurrent and metastatic tumors were often distinct from primary tumors. Compared to primary human papillomavirus (HPV)-positive tumors, many recurrent and metastatic HPV-positive tumors exhibited a molecular profile more similar to HPV-negative tumors, including enriched frequencies of TP53 mutation (3 of 20 tumors [15%]), whole genome duplication (5 of 20 tumors [25%]), and 3p deletion (11 of 20 tumors [55%]). There were high rates of TERT promoter mutation in recurrent and metastatic HPV-negative HNSCC (13 of 30 tumors [43%]), cutaneous SCC (11 of 21 tumors [52%]), basal cell carcinoma (3 of 4 tumors [75%]), and ACC (5 of 36 tumors [14%]). Activating NOTCH1 mutations were enriched in metastatic ACCs (8 of 36 tumors [22%]). Conclusions and Relevance These findings reveal the molecular landscape of advanced disease and rare cancer subtypes, both predominant challenges in head and neck oncology. To understand the repertoire of targetable alterations in advanced cancers, it is necessary to sequence recurrent and metastatic tumors. These data are important first steps toward implementation of precision head and neck oncology.
This paper references
10.1158/1078-0432.CCR-13-3310
Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas
T. Seiwert (2014)
10.1093/annonc/mdv109
Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing.
C. Chung (2015)
10.1158/1078-0432.CCR-15-2314
Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma
N. Chau (2016)
10.1001/jamaoncol.2015.5208
Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA.
Kasmintan A. Schrader (2016)
10.1002/ijc.28728
TERT promoter mutations predict worse survival in laryngeal cancer patients.
Y. Qu (2014)
10.1097/PAS.0b013e3181d9efcc
Mammary Analogue Secretory Carcinoma of Salivary Glands, Containing the ETV6-NTRK3 Fusion Gene: A Hitherto Undescribed Salivary Gland Tumor Entity
A. Skálová (2010)
10.1001/jamaoncol.2015.1313
Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
Himisha Beltran (2015)
10.1038/sj.onc.1209878
Fanconi anaemia genes and susceptibility to cancer
C. Mathew (2006)
10.1093/nar/gkw520
FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing
Ronglai Shen (2016)
10.1158/0008-5472.CAN-13-0587
Enhanced radiation sensitivity in HPV-positive head and neck cancer.
Randall J. Kimple (2013)
10.1016/j.cell.2015.05.001
Integrative Clinical Genomics of Advanced Prostate Cancer
D. Robinson (2015)
10.1016/j.drudis.2015.08.005
Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials.
David M Hyman (2015)
10.1172/JCI67201
Whole exome sequencing of adenoid cystic carcinoma.
P. Stephens (2013)
10.1126/science.1206923
Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1
N. Agrawal (2011)
10.1038/ncomms3873
Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrently-mutated genes and molecular subgroups
Arindam Nidhan K. Kishore Pradnya Shantanu Subrata Rajiv P Maitra Biswas Amin Kowtal Kumar Das Sarin Majumder (2013)
10.1126/science.aaf1490
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
N. McGranahan (2016)
10.1158/1078-0432.CCR-14-0565
Squamous Cell Carcinoma of the Oral Tongue in Young Non-Smokers Is Genomically Similar to Tumors in Older Smokers
C. Pickering (2014)
10.1038/nature14129
Comprehensive genomic characterization of head and neck squamous cell carcinomas
M. Lawrence (2015)
10.1016/j.mrfmmm.2004.06.057
Mutations induced by ultraviolet light.
G. Pfeifer (2005)
10.1126/science.2157286
Association of human papillomavirus types 16 and 18 E6 proteins with p53.
B. Werness (1990)
10.1126/science.1208130
The Mutational Landscape of Head and Neck Squamous Cell Carcinoma
Nicolas Stransky (2011)
10.18632/oncotarget.6494
Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy
Gerald Goh (2016)
10.1038/ng.2643
The Mutational Landscape of Adenoid Cystic Carcinoma
A. Ho (2013)
10.1016/j.jmoldx.2014.12.006
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.
Donavan T. Cheng (2015)
10.1158/1078-0432.CCR-14-1768
Mutational Landscape of Aggressive Cutaneous Squamous Cell Carcinoma
C. Pickering (2014)
10.1073/pnas.0906357106
HPV E6 protein interacts physically and functionally with the cellular telomerase complex
Xuefeng Liu (2009)
10.1038/nature12477
Signatures of mutational processes in human cancer
L. Alexandrov (2013)
10.1038/ng.3051
Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss
Andrew Gross (2014)
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
NA Rizvi (2015)
10.1067/j.cpsurg.2008.10.002
Cancer of the head and neck is the sixth most common cancer worldwide.
Umamaheswar Duvvuri (2009)
10.1126/science.aaa1348
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
N. Rizvi (2015)
10.18632/oncotarget.7067
Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival
Luc G T Morris (2016)
10.1016/j.celrep.2014.05.012
APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development.
Stephen Henderson (2014)
10.1073/pnas.1303607110
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal
P. Killela (2013)
10.1038/ng.2760
Pan-cancer patterns of somatic copy-number alteration
T. Zack (2013)
10.1038/ng.2702
An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers
S. Roberts (2013)
Activity of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advancedMerkel cell carcinoma (abstract)
P Nghiem (2015)
10.1038/ng.3006
The genomic landscape of nasopharyngeal carcinoma
D. Lin (2014)
10.1016/J.YPED.2010.12.093
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
James A. Stockman (2012)
10.1200/JCO.2015.33.15_SUPPL.6081
Notch1 mutations to define a subgroup of adenoid cystic carcinoma (ACC): Tumor stage, propensity to bone and liver metastasis, risk of relapse, and overall survival.
R. Ferrarotto (2015)
10.1093/annonc/mdw042
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
Alexander Drilon (2016)
10.1158/2159-8290.CD-13-0830
Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.
Alexander Stoeck (2014)
10.2741/cleaver
UV damage, DNA repair and skin carcinogenesis.
J. Cleaver (2002)



This paper is referenced by
10.1158/1078-0432.CCR-17-1561
TMEM16A/ANO1 Inhibits Apoptosis Via Downregulation of Bim Expression
Neal R. Godse (2017)
10.3389/fonc.2020.01275
TERT Promoter Mutation C228T Increases Risk for Tumor Recurrence and Death in Head and Neck Cancer Patients
Lídia M R B Arantes (2020)
10.1002/lary.27702
Prognostic impact of initial treatment in surgically salvaged recurrences of early glottic cancer.
Luca Giovanni Locatello (2018)
10.1371/journal.pgen.1008250
Molecular dissection of the oncogenic role of ETS1 in the mesenchymal subtypes of head and neck squamous cell carcinoma
Christian Gluck (2019)
10.1016/j.ebiom.2020.102905
TP53 mutational landscape of metastatic head and neck cancer reveals patterns of mutation selection
Apostolos Klinakis (2020)
The Wnt-Driven Mll 1 Epige nome Regulates Salivary Gland and Head and Neck Cancer Graphical
Q. Zhu (2019)
Aalborg Universitet Genetic rearrangements , hotspot mutations , and microRNA expression in the progression of metastatic adenoid cystic carcinoma of the salivary gland
S. Andreasen (2018)
10.1016/J.COTOX.2016.09.002
Insights into the role of NRF2 in cancer provided by cancer genomics
Petri Pölönen (2016)
University of Southern Denmark Oncogenic drivers in 11q13 associated with prognosis and response to therapy in advanced oropharyngeal carcinomas Barros-Filho,
M. C. Reis-Rosa (2019)
10.1002/lary.28694
Anti-C1GALT1 Autoantibody Is a Novel Prognostic Biomarker for Patients With Head and Neck Cancer.
Mei-Chun Lin (2020)
10.1158/0008-5472.CAN-16-2479
High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer Pathogenesis.
Ryan J. Hartmaier (2017)
10.7150/thno.20355
Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center
Ville Kytola (2017)
10.1007/978-3-319-78762-6_11
The Genome-Wide Molecular Landscape of HPV-Driven and HPV-Negative Head and Neck Squamous Cell Carcinoma
Farhoud Faraji (2018)
10.1177/0022034518769645
Precision Therapy of Head and Neck Squamous Cell Carcinoma
P.J. Polverini (2018)
10.1016/S1470-2045(19)30405-X
Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial.
D. Adkins (2019)
10.1016/j.ejso.2016.12.002
Genomic sequencing and precision medicine in head and neck cancers.
Rebecca C Hoesli (2017)
10.1016/j.oraloncology.2018.06.010
Oncogenic drivers in 11q13 associated with prognosis and response to therapy in advanced oropharyngeal carcinomas.
Mateus C Barros-Filho (2018)
10.1016/j.oraloncology.2020.104631
Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic head and neck squamous cell carcinoma.
Rachel Galot (2020)
10.1016/j.oooo.2020.02.015
Promoter region mutations of the telomerase reverse transcriptase (TERT) gene in head and neck squamous cell carcinoma.
Ismail Yılmaz (2020)
10.1007/978-3-319-78762-6_4
Transforming Growth Factor Beta (TGF-β) Signaling in Head and Neck Squamous Cell Carcinoma (HNSCC)
Alexander E. Kudinov (2018)
10.1016/J.CRITREVONC.2019.01.018
Prognostic and predictive factors in recurrent and/or metastatic head and neck squamous cell carcinoma: A review of the literature.
P. Bossi (2019)
10.1002/ijc.32412
Identification of prognostic molecular biomarkers in 157 HPV-positive and HPV-negative squamous cell carcinomas of the oropharynx.
Snjezana Dogan (2019)
10.1038/srep46102
Genetic Mutation and Exosome Signature of Human Papilloma Virus Associated Oropharyngeal Cancer
Anbarasu Kannan (2017)
10.1371/journal.pone.0191701
Genomic analysis of head and neck cancer cases from two high incidence regions
S. Perdomo (2018)
10.18632/oncotarget.24800
Genetic rearrangements, hotspot mutations, and microRNA expression in the progression of metastatic adenoid cystic carcinoma of the salivary gland
S. Andreasen (2018)
10.1186/s12910-020-0457-8
Structural racism in precision medicine: leaving no one behind
Lester Darryl Geneviève (2020)
10.1177/0194599817709236
Preoperative Tracheostomy Is Associated with Poor Disease-Free Survival in Recurrent Laryngeal Cancer
Andrew C. Birkeland (2017)
10.3389/fonc.2019.01175
STAT3 Promotes Invasion and Aerobic Glycolysis of Human Oral Squamous Cell Carcinoma via Inhibiting FoxO1
Min Zheng (2019)
10.1172/jci.insight.99327
The mutational landscape of recurrent versus nonrecurrent human papillomavirus-related oropharyngeal cancer.
R Alex Harbison (2018)
10.1038/s41598-019-49212-y
Clinical, pathophysiologic, and genomic analysis of the outcomes of primary head and neck malignancy after pulmonary metastasectomy
Hsueh-Ju Lu (2019)
10.7150/jca.33635
NT-3/TrkC Axis Contributes to the Perineural Invasion and the Poor Prognosis in Human Salivary Adenoid Cystic Carcinoma
Huan Li (2019)
10.1111/exd.13356
Loss of INK4a/Arf gene enhances ultraviolet radiation‐induced cutaneous tumor development
Israr Ahmad (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar